In last trading session, Nuvation Bio Inc (NYSE:NUVB) saw 2.75 million shares changing hands with its beta currently measuring 1.39. Company’s recent per share price level of $2.62 trading at $0.08 or 3.15% at ring of the bell on the day assigns it a market valuation of $877.12M. That closing price of NUVB’s stock is at a discount of -58.78% from its 52-week high price of $4.16 and is indicating a premium of 53.82% from its 52-week low price of $1.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.64 million shares which gives us an average trading volume of 1.54 million if we extend that period to 3-months.
For Nuvation Bio Inc (NUVB), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.13 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Nuvation Bio Inc (NYSE:NUVB) trade information
Upright in the green during last session for gaining 3.15%, in the last five days NUVB remained trading in the green while hitting it’s week-highest on Thursday, 11/07/24 when the stock touched $2.62 price level, adding 2.96% to its value on the day. Nuvation Bio Inc’s shares saw a change of 73.51% in year-to-date performance and have moved 18.55% in past 5-day. Nuvation Bio Inc (NYSE:NUVB) showed a performance of 18.55% in past 30-days. Number of shares sold short was 9.97 million shares which calculate 5.79 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 6 to the stock, which implies a rise of 56.33% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -90.84% in reaching the projected high whereas dropping to the targeted low would mean a loss of -90.84% for stock’s current value.
Nuvation Bio Inc (NUVB) estimates and forecasts
Statistics highlight that Nuvation Bio Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -21.32% of value to its shares in past 6 months, showing an annual growth rate of -502.86% while that of industry is 16.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2024.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Insiders are in possession of 27.01% of company’s total shares while institution are holding 44.01 percent of that, with stock having share float percentage of 60.29%. Investors also watch the number of corporate investors in a company very closely, which is 44.01% institutions for Nuvation Bio Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at NUVB for having 28.82 million shares of worth $84.16 million. And as of 2024-06-30, it was holding 13.1578 of the company’s outstanding shares.
The second largest institutional holder is ECOR1 CAPITAL, LLC, which was holding about 19.21 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.7696 of outstanding shares, having a total worth of $56.09 million.
